Articles

Two years of trastuzumab provide no benefit over the standard of 1 year of trastuzumab therapy for human epidermal growth factor receptor 2–positive (HER2+) breast cancer, according to an 8-year follow-up of the Herceptin Adjuvant (HERA) trial reported by Martine Piccart, MD, president of the European Society for Medical Oncology and chair of the Breast International Group, Institut Jules Bordet, Brussels, Belgium. Read More ›

A 10-year follow-up of the 2-part UK Standardisation of Breast Radiotherapy Trial (START) supports the 5-year findings, which demonstrated that a shorter course of adjuvant radiation therapy is equivalent to a 5-week course of radiation for women with invasive breast cancer. Read More ›

Cognitive changes identified in patients undergoing chemotherapy are common and referred to as “chemo brain.” Read More ›

A recent study found that national guidelines pertaining to the average number of polyps routinely detected during colonoscopy may be too low. Read More ›

Recent studies have shown that, when compared with the conventional x-ray test of barium enema, a CT colonography is more effective when an examination of bowel cancer symptoms is required. Read More ›

Although maintaining a healthy diet is important for all cancer patients, managing the time and resources involved with testing cancer patients for malnutrition can be a challenge for clinics. Read More ›

Although the patients had no intention of quitting their habit, nicotine lozenges and tobacco-free snuff helped smokeless tobacco users to significantly reduce their tobacco use, according to a recent study. Read More ›

New research shows that focusing on cognitive, emotional, physical, social, and spiritual well-being through therapy interventions improves the patient’s quality of life considerably during cancer treatment. Read More ›

Multiple myeloma (MM) accounts for 10% to 15% of all hematologic malignancies, and is the cause of 20% of the deaths that result from blood and bone cancers. Read More ›

Novel therapies for patients with multiple myeloma (MM) continue to show improved outcomes for a population that as little as 8 years ago had few options. Read More ›